Adopted Trials - Lung (sclc)
Acronym: EORTC 08062
Full Title
Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus etoposide-cisplatin as first-line treatment in patients with extensive stage SCLC (ES)
Treatment: Chemotherapy
Phase: 2
Current status: Open to recruitment
Chief Investigator: Mary O'Brien
Type of trial: Early Phase
